A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors | MicrobiomeTrials← Back to trialsNCT07636785
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-06Est. Completion: 2031-05
Enrollment target: 111 participants Locations- HonorHealth Research Institute, Scottsdale, Arizona, United States
Other microbiome trials you might be interested in
Hepatocellular Carcinoma (HCC)CirrhosisRisk Prediction for Liver CancerEpigenomics
This study aims to evaluate the role of the circulating epigenetic biomarker mSEPT9 in predicting the risk of hepatocell…
Vandœuvre-lès-Nancy, FranceEst. completion Jun 3, 2033
Hepatocellular Carcinoma (HCC)Artificial IntelligentAdjuvant ChemoradiotherapyTACELenvatinibLiver Surgery
Hepatocellular carcinoma (HCC) is a high-mortality global malignancy with a heavy disease burden in China. Although cura…
Hangzhou, ChinaEst. completion Jan 1, 2029
Fatty Liver
The newly adapted definition for MASLD includes evidence for hepatic steatosis by imaging or biopsy with at least one of…
Sohag, EgyptEst. completion Jan 1, 2027